What is PepGen?
Founded in 2018 and headquartered in Cambridge, Massachusetts, PepGen is a pioneer in the development of next-generation oligonucleotide therapeutics. The company focuses on the intersection of molecular biology and clinical medicine, specifically targeting neuromuscular and neurologic diseases that have historically lacked effective treatment options. By utilizing advanced delivery platforms, PepGen seeks to enhance the efficacy and safety profiles of its therapeutic candidates, thereby establishing a strong competitive moat within the high-growth biotechnology sector. The firm's market position is bolstered by its strategic alignment with academic research institutions and specialized venture philanthropy organizations, ensuring a steady trajectory from laboratory discovery to clinical application.
How much funding has PepGen raised?
PepGen has raised a total of $56.3M across 2 funding rounds:
Series A
$45M
Unspecified
$11.3M
Series A (2020): $45M with participation from Oxford Sciences Enterprises, RA Capital Management LP, CureDuchenne, and Oxford University
Unspecified (2021): $11.3M led by Viking Global Investors, RA Capital Management, CureDuchenne, and Oxford Sciences Enterprises
Key Investors in PepGen
Viking Global Investors
A global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
Oxford Sciences Enterprises
An independent investment company created to found, fund, and build transformational businesses via a unique partnership with the University of Oxford.
CureDuchenne
A nonprofit organization dedicated to curing Duchenne muscular dystrophy through a venture philanthropy model that funds innovative research and treatment access.
What's next for PepGen?
Looking ahead, PepGen is poised to utilize its recent capital injection to scale its clinical operations and expand its internal research capabilities. The strategic roadmap involves prioritizing the advancement of its lead candidates through regulatory milestones while simultaneously exploring new therapeutic indications for its delivery platform. As the company transitions into a more mature phase of its lifecycle, the focus will likely shift toward establishing commercial partnerships and optimizing manufacturing processes to support large-scale clinical trials. Investors and industry observers will be closely monitoring the firm's progress in demonstrating long-term safety and efficacy data, which will be critical for future valuation growth and potential market entry.
See full PepGen company page
